Pet Longevity Treatments Move Toward Market
Several companies are developing gene therapies and drugs aimed at age-related diseases in dogs and cats.
Updated on Nov. 4, 2026 in Pet Health
Live Poll
Would you pay for an expensive gene therapy to extend your pet's life?
Companies including Rejuvenate Bio, Genflow Biosciences and The Cat Health Company are developing treatments for age-related conditions in pets. Efforts range from gene therapies for heart and muscle disease to drugs for kidney disease and muscle loss in cats.
Why it matters
Pet owners and veterinarians may gain new options for treating chronic age-related illness, which has traditionally been managed with limited therapies. Companies are also exploring probiotic pet food and medicines originally developed for humans, suggesting cross-species research could accelerate progress.
The Cat Health Company has two compounds in clinical trials, while Rejuvenate Bio's mitral valve disease gene therapy targets the most common heart condition in dogs. The extraction does not report trial outcomes, efficacy results, or sample sizes for any program.
The players
Rejuvenate Bio
A San Diego, California company developing a gene therapy for mitral valve disease, the most common heart condition in dogs, and working to lower the cost of gene therapy production.
Genflow Biosciences
A company developing gene therapies aimed at extending dogs' lifespans and reducing age-related muscle loss.
The Cat Health Company
A Bucharest-based company developing drugs for muscle loss and kidney disease in cats, with two compounds currently in clinical trials.
The details
Rejuvenate Bio, based in San Diego, is developing a gene therapy for mitral valve disease, and has worked to reduce the cost of producing such complex treatments. Genflow Biosciences is developing gene therapies to extend dogs' lifespans and reduce age-related muscle loss, while The Cat Health Company, based in Bucharest, targets muscle loss and kidney disease in cats.
Roadmap
Gene therapy, long developed for rare human inherited diseases, is now being applied to common age-related conditions in companion animals. Companies are also adapting probiotics and medicines originally developed for humans, suggesting pet health research is becoming a testing ground for broader cross-species approaches.
Pet owners whose animals have heart or muscle conditions may eventually have access to new gene therapies, though none are described as available yet. Owners of cats with kidney disease or muscle loss may watch for future drug options as the compounds in clinical trials progress.
The takeaway
Age-related pet illness is becoming a target for therapies once reserved for human medicine, so owners of older dogs and cats should keep track of emerging options with their veterinarians. Treatments remain in development, so current care decisions should rest on established veterinary guidance.
Further reading
For broader context on animal wellness trends, explore Pet Health coverage.
Source note: This article includes information reported by Qazinform.
Live Poll
Would you pay for an expensive gene therapy to extend your pet's life?
